XBiotech
XBIT
39 hedge funds and large institutions have $14.2M invested in XBiotech in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 3 closing their positions.
200% more call options, than puts
Call options by funds: $3K | Put options by funds: $1K
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
5% more funds holding
Funds holding: 37 → 39 (+2)
2% more capital invested
Capital invested by funds: $14M → $14.2M (+$250K)
0.71% more ownership
Funds ownership: 10.98% → 11.69% (+0.71%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$533K |
| 2 |
Man Group
London,
United Kingdom
|
+$232K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$215K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$105K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$97K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$540K |
| 2 |
Renaissance Technologies
New York
|
-$63K |
| 3 |
Two Sigma Investments
New York
|
-$21.5K |
| 4 |
Two Sigma Advisers
New York
|
-$20.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.3K |
XBIT Hedge Fund Activity: Q4 2023 in Review
39 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2023, worth a combined $14.2M — up 1.8% from $14M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new XBIT positions and 3 closed out — a net gain of 2 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $533K. The largest seller was Millennium Management, cutting an estimated $540K.
- 39 institutional investors held XBiotech (XBIT) as of Q4 2023, up from 37 in Q3 2023.
- Funds reported $14.2M of XBiotech stock for Q4 2023, up 1.8% quarter-over-quarter.
- 5 funds opened new XBiotech positions in Q4 2023 and 3 closed out, a net change of +2 holders.
- The largest XBiotech buyer in Q4 2023 was Morgan Stanley, an estimated $533K added.
- The largest XBiotech seller in Q4 2023 was Millennium Management, an estimated $540K sold.
Based on aggregated 13F filings for Q4 2023.